The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors ...

Major Parkinson’s breakthrough as new pill offers hope of treating symptoms and has fewer side-effects - Trial found patients on solengepras had 37 minutes less ‘off’ time each day when dopamine drugs ...

A new daily pill could help people with Parkinson’s disease live more of their life without symptoms, a trial has found.

Cerevance plans to determine next steps towards potential approval for solengepras in Parkinson’s with the FDA.

Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2Statistically ...

Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual ...

The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.

It’s improving quality of life. Parkinson’s drugs are meant to keep patients in what’s called their “on state,” providing improvement in coordination and stiffness. But as the drugs wear off between ...

Boston, Oct. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, "Anti-Parkinson's Drugs: Global Markets to 2030" is projected to grow from $6.1 billion in 2025 to $9.2 ...

(HealthDay)—Results of a small study suggest that Parkinson's patients seem to improve if they think they're taking a costly medication. The findings have been published online Jan. 28 in Neurology.

A nationwide Finnish cohort study found that people with Parkinson's disease receive anti-osteoporosis medications at rates ...